Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review of 48 scientific sources identifies various treatment methods, including drug and non-drug approaches, for oral lichen planus, highlighting side effects and emphasizing the need for more effective and personalized treatments due to existing contraindications, especially in severe cases.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that the pH levels of relaxers tested were corrosive to the skin and may contribute to alopecia in females with afro-textured hair.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that a high dose of LustrivaTM, containing biotin and silicon, significantly increased hair thickness and reduced facial wrinkle depth in women with thinning hair compared to a placebo, without any reported adverse events.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This case report highlighted an instance of lichen spinulosus emerging as a new cutaneous sequela in a boy following toxic epidermal necrolysis, responding to treatment with ammonium lactate.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.

This case study reports that a 35-year-old woman developed nonscarring alopecia following the cosmetic use of poly-L-lactic acid on her face and hairline.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

In this study, a patient with lichen planopillaris experienced complete resolution of itching and hair shedding following treatment with a new platelet-rich plasma regimen, marking the first reported success in this context.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

The researchers reported that low-dose methotrexate, in combination with surgical dilatation and local treatments, may improve symptoms in patients with severe stenosing vulvovaginal lichen planus.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This report describes a case of trachyonychia with associated various types of lichen planus in a young male, highlighting the importance of accurate diagnosis for effective treatment.

In this study, shampoos containing sodium lauroyl methylaminopropionate showed superior coacervate formation and lubrication on wet hair, outperforming other amino acid surfactants and suggesting potential for creating low-irritation, high-performance hair products.

In this case report, a 53-year-old woman with Little-Graham-Piccardi-Lassueur-Syndrome responded well to a treatment regimen of hydroxychloroquine, methotrexate, and other therapies, effectively halting the progression of this rare dermatosis characterized by alopecia and hyperkeratotic eruptions.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.